GGrantIndex
← Leaderboards

Andrew A Pieper

Johns Hopkins University

Google Scholar ↗PubMed ↗ORCID ↗
$7,901,653
Attributed
$19,647,248
Total exposure
13
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.8M · FY2009–25
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$19,647,248 · 10
VA$0 · 3

By mechanism

R01$8,566,389 · 2
RM1$6,903,660 · 1
RF1$2,394,473 · 1
R21$889,606 · 2
P30$865,095 · 3
F30$28,025 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposPharmaceutical PreparationsNeuronsBrainPre-ClinicalDesignLaboratoriesPreventIn VivoTraumatic Brain InjuryMediatingAnimal ModelNerve DegenerationBaseSafetyComplexMouse ModelFutureNovel TherapeuticsCellsAffectAdultFoundationsLead

Grant awards (39)

Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,354,462
RM1 · FY2025 · GM
Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches$783,415
R01 · FY2025 · AG
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease$0
I01 · FY2025 · VA · contact PI
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,354,462
RM1 · FY2024 · GM
Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches$796,355
R01 · FY2024 · AG
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$94,538
RM1 · FY2024 · GM
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$39,393
RM1 · FY2024 · GM
Alzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug Repurposing$2,394,473
RF1 · FY2023 · AG
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,354,462
RM1 · FY2023 · GM
Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches$811,605
R01 · FY2023 · AG
Translational and Therapeutics Core$201,717
P30 · FY2023 · AG · contact PI
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease$0
I01 · FY2023 · VA · contact PI
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,345,312
RM1 · FY2022 · GM
Translational and Therapeutics Core$398,797
P30 · FY2022 · AG · contact PI
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration$1,361,031
RM1 · FY2021 · GM
Translational and Therapeutics Core$201,717
P30 · FY2021 · AG · contact PI
Translational Therapeutics Core$62,864
P30 · FY2020 · AG · contact PI
Photosensitivity as a preclinical assessment for treatment of post-traumatic headache$0
I01 · FY2020 · VA
Neuroprotective Small Molecules as Novel Treatments for ALS$0
I01 · FY2020 · VA · contact PI
Neuroprotective Small Molecules as Novel Treatments for ALS$0
I01 · FY2020 · VA · contact PI
Photosensitivity as a preclinical assessment for treatment of post-traumatic headache$0
I01 · FY2019 · VA
Assessment of the effects of emergent helicopter transport on stroke in a rodent model$190,625
R21 · FY2018 · NS
Photosensitivity as a preclinical assessment for treatment of post-traumatic headache$0
I01 · FY2018 · VA
Neuroprotective Small Molecules as Novel Treatments for ALS$0
I01 · FY2018 · VA · contact PI
Assessment of the effects of emergent helicopter transport on stroke in a rodent model$228,750
R21 · FY2017 · NS
Neuroprotective Small Molecules as Novel Treatments for ALS$0
I01 · FY2017 · VA · contact PI
Photosensitivity as a preclinical assessment for treatment of post-traumatic headache$0
I01 · FY2017 · VA
Photosensitivity as a preclinical assessment for treatment of post-traumatic headache$0
I01 · FY2016 · VA
Neuroprotective Small Molecules as Novel Treatments for ALS$0
I01 · FY2016 · VA · contact PI
Neuroprotective Small Molecules as Novel Treatments for ALS$0
I01 · FY2015 · VA · contact PI
Efficacy of a Novel Neuroprotective Compound in Nonhuman Primate$39,103
R21 · FY2014 · NS
Discovery, characterization and preclinical development of pro-neurogenic drugs$1,184,388
R01 · FY2013 · MH
Efficacy of a Novel Neuroprotective Compound in Nonhuman Primate$186,554
R21 · FY2013 · NS
Discovery, characterization and preclinical development of pro-neurogenic drugs$1,238,447
R01 · FY2012 · MH
Efficacy of a Novel Neuroprotective Compound in Nonhuman Primate$244,574
R21 · FY2012 · NS
Discovery, characterization and preclinical development of pro-neurogenic drugs$1,243,305
R01 · FY2011 · MH
Discovery, characterization and preclinical development of pro-neurogenic drugs$1,260,917
R01 · FY2010 · MH
Discovery, characterization and preclinical development of pro-neurogenic drugs$1,247,957
R01 · FY2009 · MH
IN VIVO MODULATION OF THE IP3R BY PHOSPHORYLATION$28,025
F30 · FY2000 · MH